2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 322

The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort
Abstract Number: 3018

The Analysis of Severity of Arthritis in the Intestinal Microbiota-Humanized Mice
Abstract Number: 449

the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: Reliability, Responsiveness, and Interpretation
Abstract Number: 1085

The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients
Abstract Number: 921

The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Abstract Number: 165

The Apparent Diffusion Coefficient As a Quantitative Imaging Biomarker of Therapeutic Response in Enthesitis-Related Arthritis
Abstract Number: 2101

the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex
Abstract Number: 2194

The Association Between Arthritis and Carpal Tunnel Syndrome: National Health Interview Survey, 2010
Abstract Number: 3161

The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis
Abstract Number: 1662

The Association Between Radiologic Progression and Serum Levels of Potential Markers of Bone Formation in Ankylosing Spondylitis Patients
Abstract Number: 3157

The Association Between Sonographic Enthesitis and Radiographic Damage in Psoriatic Arthritis
Abstract Number: 2189

The Association of Arthritis and Lung Diseases: A Population-Based Study
Abstract Number: 515

The Association of Body Mass Index with the Severity of Magnetic Resonance Imaging-Detected Inflammation at Presentation; Opposite Effects in Early Rheumatoid Arthritis Compared to Other Arthritides and an Asymptomatic Population
Abstract Number: 1552

The Association of Fatigue, Comorbidities and Anti Rheumatic Drugs in Rheumatoid Arthritis: Results from French Cohort Study of Comorbidities
Abstract Number: 2027

The Association of Light and Moderate-to-Vigorous Walking with Incident Poor Health Outcomes over Two Years in People with or at High Risk of Knee Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].